Age and sex-specific risks of myocarditis and pericarditis following Covid-19 messenger RNA vaccines

Bottom line and this study out today is telling us what we already knew from prior studies across the last over one year. The study shows that vaccination/injection/inoculation using both mRNA vaccines (Pfizer and Moderna) was related to an increased risk of myocarditis and pericarditis within the first 7 days post vaccination. The study showed that the relationships/associations were especially marked after the second dose, and were existent for both males and females. The study also revealed a trend of enhanced risks towards younger age groups. Moreover, a significant risk was also emerged among males greater than 30 years of age to develop myocarditis and among females over 30 years of age to develop a pericarditis post vaccination.
Specifically, this study (Figures 1 and 2) showed us that for the two vaccines, ‘the risk of myocarditis was increased in the seven days post vaccination. For the BNT162b2 vaccine (Pfizer), odds ratios were 1.8 (95% confidence interval [CI]: 1.3–2.5) for the first dose and 8.1 (95% CI, 6.7–9.9) for the second. The association was stronger for the mRNA-1273 vaccine (Moderna) with odds-ratios of 3.0 (95% CI, 1.4–6.2) for the first dose and 30 (95% CI, 21–43) for the second. The risk of pericarditis was increased in the seven days following the second dose of both vaccines, with odds ratios of 2.9 (95% CI, 2.3–3.8) for the BNT162b2 vaccine and 5.5 (95% CI, 3.3–9.0) for the mRNA-1273 vaccine. Vaccination in the previous 8 to 21 days, with either the BNT162b2 or mRNA-1273 vaccine was not associated with a risk of myocarditis or pericarditis.’

Le Vu et al, Nature Communications, risk includes 10x within just 7 days of taking the vaccine. The absolute risks are considerably greater when the occurrence window is opened. The risks shown are real and are just the tip of the iceberg. Concerning literature.

Age-and-sex-specific-risks-of-myocarditis-and-pericarditis

View PDF Directly: https://www.nature.com/articles/s41467-022-31401-5.pdf

Source: https://www.nature.com/articles/s41467-022-31401-5?utm_source=substack&utm_medium=email

The impact of immune history and variant on SARS-CoV-2 viral kinetics and infection rebound

Hay et al, Harvard, mandated products backfiring and making the PCR stay positive longer in compliant compared to sage unjected subjects. Employers should look carefully at ill-advised mandates and review these curves as compliant employees get sick and want to return to work.

The-impact-of-immune-history-and-variant-on-SARS-CoV-2

View PDF Directly: https://www.medrxiv.org/content/10.1101/2022.01.13.22269257v2.full.pdf

Source: https://www.medrxiv.org/content/10.1101/2022.01.13.22269257v2

Intramyocardial Inflammation after COVID-19 Vaccination: An Endomyocardial Biopsy-Proven Case Series

Baumeier et al, Berlin, cardiac biopsies reveal giant cell and presence of Spike protein within myocardial tissue. Giant cells are predictive of cardiac death. Presence of Spike evidence of causality for mandated products producing heart damage. @HighWireTalk @fynn fan

Intramyocardial-Inflammation-after-COVID-19-Vaccination

Source: https://www.mdpi.com/1422-0067/23/13/6940

SARS-CoV-2 spike protein expressing epithelial cells promotes senescence associated secretory phenotype in endothelial cells and increased inflammatory response

Meyer, St. Louis Univ, Spike causes cells to age more rapidly across an array of in vitro measures. Repeated doses every six months may accelerate the aging process; congruent with reports of increasing and more aggressive cancers and progression of ASCVD. RX ideas in Figure.

Spike-protein-promotes-senescence-associated-secretory-phenotype

View PDF Directly: https://www.biorxiv.org/content/10.1101/2021.04.16.440215v1.full.pdf

Source: https://www.biorxiv.org/content/10.1101/2021.04.16.440215v1

The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic

Omicron-highly-resistant-against-antibody-mediated-neutralization

View PDF Directly: https://www.cell.com/action/showPdf?pii=S0092-8674%2821%2901495-1

Source: https://pubmed.ncbi.nlm.nih.gov/35026151/

The emergence and ongoing convergent evolution of the SARS-CoV-2 N501Y lineages

The-emergence-evolution-of-SARSCoV2-N501Y-lineages

View PDF Directly: https://www.cell.com/action/showPdf?pii=S0092-8674%2821%2901050-3

Source: https://pubmed.ncbi.nlm.nih.gov/34537136/

Structural insight into SARS-CoV-2 neutralizing antibodies and modulation of syncytia

Structural-insight-into-SARSCoV2-neutralizing-antibodies

View PDF Directly: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8064868/pdf/main.pdf

Source: https://pubmed.ncbi.nlm.nih.gov/33974910/

Lectins enhance SARS-CoV-2 infection and influence neutralizing antibodies

Lectins-enhance-SARS-CoV-2-infection

View PDF Directly: https://www.nature.com/articles/s41586-021-03925-1.pdf

Source: https://pubmed.ncbi.nlm.nih.gov/34139176/

An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies

An-infectivity-enhancing-site-on-spike-targeted-by-antibodies

Direct PDF: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8142859/pdf/main.pdf

Source: https://pubmed.ncbi.nlm.nih.gov/34139176/

Risk of rapid evolutionary escape from biomedical interventions targeting SARS-CoV-2 spike protein

Van Egeren et al, Harvard, PLOS, explains how mutations render the mandated products useless but still has enough RBD integrity to cause infection.   The worldwide failure of the program occurred with a narrow band of epitopes had no hope for durable protection.  Anticipated.

Risk-of-rapid-evolutionary-escape-from-biomedical-interventions

View PDF Directly: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8081162/pdf/pone.0250780.pdf

Source: https://pubmed.ncbi.nlm.nih.gov/33909660/